| Autor: |
Hami Reza Ebrahimnegad, Zeinab Shankayi, Mohammad Hosein Eidnezhad, Mohammad Mahdi Asadi, Mohammad Hassan Mirasheh, Mohammad Nikpouraghdam, Farideh Bahrami, Maryam Shahriari, Tahereh Mohammadzadeh, Hassan Amanpoor, Abdol Majid Cheraghali, Mahdi Mashhadi Akbar Boojar, Mohammad Mahdi Poorhaji |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Bulletin of Pharmaceutical Sciences. Assiut. 44:89-97 |
| ISSN: |
1110-0052 |
| DOI: |
10.21608/bfsa.2021.174134 |
| Popis: |
Purpose: The propagation of the new coronavirus, COVID 19, is still a major priority for many countries around the world. Because of the lack of effective certain antiviral therapy for COVID 19. Special medicinal protocols are needed in medical centers to reduce the mortality rate. Methods: Due to constant change of national pharmacotherapy protocols for COVID-19 patients, this study compares the outcomes of three specific pharmacotherapy regimens (Table 1) and the combination of all 3 regimens for management of 614 COVID-19 patients hospitalized in Baqiyatallah hospital in Tehran, this hospital became a referral centers for receiving COVID 19 patients in Iran. Results: The more reliable result of treatments belongs to regimen 3 which indicated 98.26% recovered patients and 1.15% mortality rate and the lowest period of hospitalization with 4.4±0.21 days’ duration. Conclusion: It seems that regimen 3 (with a special combination of antiviral and Azithromycin ant anti-inflammatory drugs) had the best result in improving patients with COVID 19 and this result has not conflict with the comorbidity status of patients. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
